Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Quest Diagnostics has a Zacks Rank of #3 (Hold), a VGM Score of A, and a Value Style Score of B, with a forward P/E of 21.63. Six analysts raised fiscal 2026 earnings estimates over the past 60 days, lifting the consensus by $0.08 to $11.23 per share; DGX’s average earnings surprise is +6.2%. The article presents the stock as a long-term value candidate but reports no new company announcement or share-price reaction.

Analysis

DGX: quality-screen signal, not yet a valuation catalyst

The earnings-estimate change cited is less than 1% of the new FY26 EPS estimate: supportive, but too small on its own to establish a durable earnings inflection. A model-driven “value” label is also weak evidence of mispricing; a forward multiple around 22x requires sustained earnings delivery, and the article supplies no peer comparison or cash-flow basis for calling it cheap.

The more durable mechanism is scale in outsourced testing: if hospitals continue shifting lab operations to external providers, Quest could gain volume and deepen customer integration. The countervailing risk is that scale does not guarantee pricing power—reimbursement pressure, hospital bargaining, wage and logistics costs, or a less favorable test mix can absorb incremental volume. Labcorp is the most relevant competitive read-through; compare organic volume, pricing/mix, and margins rather than relying on relative valuation scores.

Timing: Near term, this promotional research item is unlikely to change fundamentals. Over 1–3 months, the signal strengthens only if estimate increases broaden and reported volume/mix support them. Over 6–18 months, hospital outsourcing and cost execution matter more than style scores. The contrarian point: a defensive, steady compounder can be fairly valued rather than undervalued; consensus may be over-weighting past earnings surprises and under-weighting reimbursement and cost pressure. No trade is warranted on this article alone. Falsify the constructive view if estimates turn down or operating results show weakening volume/mix or margin deterioration.

Key Decisions for Investors

• Do not add DGX solely on the Zacks style designation or the small estimate revision; treat the article as a screening prompt, not new fundamental evidence.
• Watch the next results and guidance for organic test volume, pricing/mix, operating margin, and any reimbursement or hospital-contract changes; verify whether estimate revisions broaden before considering an entry.
• For relative-value work, compare Quest with Labcorp on growth, margin trajectory, and valuation using current filings; avoid a pair trade until those data establish a meaningful divergence.
• Reassess the constructive thesis if consensus EPS revisions reverse or reported volume/mix and margins weaken; absent confirmation, maintain a neutral stance.